Novo Nordisk’s Wegovy captures 19% of AI chatbot mentions for weight-loss, but adjusted Q1 revenue dropped 4% and stock remains 36% below last year amid margin pressures.<\/p>\n
Patients querying ChatGPT or Claude for weight-loss treatments are far more likely to encounter Wegovy than any rival. A new index tracking visibility in artificial-intelligence chatbots shows Novo Nordisk\u2019s flagship obesity drug commands 19 percent of all AI-generated mentions, outpacing Eli Lilly\u2019s Zepbound and its own diabetes drug Ozempic, which sits at 13 percent. That digital dominance is a powerful demand signal, but it does little to paper over the margin pressures that continue to hold the stock in check.<\/p>\n
Danish Pharma Keeps the Economy Humming<\/p>\n
Denmark\u2019s real gross domestic product expanded 1.9 percent in the first quarter of 2026 from the prior three months, a figure that owes much to a single sector. Industrial production jumped 8.6 percent in March alone, and 5.1 percent over the full quarter. Strip out pharmaceuticals, however, and the broader industry managed only 1.6 percent growth.<\/p>\n
The pharmaceutical sub-sector itself swung even harder: output surged 15.0 percent in March and 12.0 percent across the quarter. With pharma representing 20 percent of the industrial index, its multiplier effect on the headline numbers is obvious. For Novo Nordisk, the company that anchors Denmark\u2019s drug-manufacturing profile, this macro tailwind offers a favourable backdrop \u2014 but not one that automatically translates into higher earnings per share.<\/p>\n
Mixed Signals in the First-Quarter Results<\/p>\n
Novo Nordisk reported a 32 percent rise in revenue at constant exchange rates for the opening quarter of 2026. Strip out the reversal of a provision related to the US 340B programme, however, and top-line growth turned negative, falling 4 percent on an adjusted basis. The disconnect between reported and underlying performance has become a defining feature of the narrative.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n The obesity business, measured on an adjusted basis, saw sales climb 22 percent in constant-currency terms. But the US market told a different story: adjusted revenues there dropped 11 percent, hammered by lower realised pricing. International revenue rose 6 percent, supported by higher volumes.<\/p>\n The operating profit picture was similarly split. Statutory operating profit jumped 65 percent at constant currencies. The adjusted version fell 6 percent. Those twin tracks \u2014 headline strength versus core weakness \u2014 explain why the stock has struggled to shake off its longer-term malaise.<\/p>\n Stock Remains in a Deep Hole<\/p>\n Novo Nordisk shares closed at \u20ac38.85 on Wednesday, or \u20ac38.87 in the latest session, with a modest intraday gain. The month-on-month recovery has been respectable: a 15.69 percent advance, or roughly 13 percent depending on the reference point. The stock now sits 12.47 percent above its 50-day moving average.<\/p>\n Yet the longer view is far less forgiving. The share price has shed 13.04 percent since the start of the year and 35.68 percent over the past twelve months. The distance to the 52-week high remains more than 44 percent. Lagging the 200-day moving average by 8.08 percent, the recovery has all the hallmarks of a bear-market bounce in need of fundamental support.<\/p>\n Pill Volume Picks Up, but Price Pressure Persists<\/p>\n One catalyst gaining traction is the new Wegovy oral tablet. Since its US launch in January, prescriptions have already topped two million. First-quarter sales from the pill alone reached 2.25 billion Danish kroner. That kind of uptake reinforces Novo Nordisk\u2019s grip on the GLP-1 market, but the digital edge \u2014 including AI search visibility \u2014 also helps funnel patients into the pipeline.<\/p>\n